CYBN Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cybin Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.82 |
| 52 Week High | US$21.66 |
| 52 Week Low | US$6.50 |
| Beta | 0.88 |
| 11 Month Change | -10.16% |
| 3 Month Change | -3.57% |
| 1 Year Change | -44.06% |
| 33 Year Change | -80.86% |
| 5 Year Change | n/a |
| Change since IPO | -62.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYBN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -15.3% | 1.6% | 2.2% |
| 1Y | -44.1% | 10.0% | 31.7% |
Return vs Industry: CYBN underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: CYBN underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CYBN volatility | |
|---|---|
| CYBN Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CYBN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CYBN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | Doug Drysdale | www.cybin.com |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.
Cybin Inc. Fundamentals Summary
| CYBN fundamental statistics | |
|---|---|
| Market cap | US$206.78m |
| Earnings (TTM) | -US$88.49m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs CYBN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYBN income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$123.69m |
| Earnings | -CA$123.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CYBN perform over the long term?
See historical performance and comparison